Form 4: Arbutus Biopharma Director Rewolinski Granted Stock Options

Director Melissa Rewolinski of Arbutus Biopharma Corp. was granted stock options for 67,000 common shares on May 23, 2024, fully vested and exercisable immediately.

Summary

• Melissa Rewolinski, a director at Arbutus Biopharma Corp, received stock options on May 23, 2024.
• The options grant the right to buy 67,000 common shares at an exercise price of $3.28 per share.
• The options are fully vested and exercisable as of the grant date.
• The options expire on May 23, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is a standard practice.

Positives

• The options are fully vested and exercisable immediately, providing immediate potential benefit to the director.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, aligning the interests of directors with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded biopharmaceutical companies.
• The size of the grant (67,000 shares) would need to be compared to grants at similar companies to determine if it is above or below average.
• Companies like Gilead Sciences, Amgen, and Vertex Pharmaceuticals also use stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
• The grant has a dilutive effect on existing shareholders, although the impact is likely minimal.

Key Dates